Second-generation BCR–ABL inhibitors have also demonstrated some activity against CML stem cells, providing support for future investigation into dasatinib in achieving a molecular cure (Defina et al. 2012; Hiwase et al. 2010; Mustjoki et al. 2011). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.